Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia

Giuliana Rizzuto1,2 | Matteo Leoncin3 | Silvia Imbergamo3 | Daniela Taurino1 | Maria Caterina Mico1 | Manuela Tosi1 | Anna Michelato1 | Ksenija Buklijas1 | Orietta Spinelli1 | Federico Lussana1 | Federica Lessi3 | Marco Pizzi4 | Laura Bonaldi5 | Gianni Binotto3 | Alessandro Rambaldi1,2 | Carmela Gurrieri3

1Hematology and Bone Marrow Transplantation Unit, Azienda Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
2Department of Oncology-Hematology, Universita’ degli Studi di Milano, Milan, Italy
3Hematology and Clinical Immunology Unit, Universita’ degli Studi di Padova, Padua, Italy
4Department of Pathology, Universita degli Studi di Padova, Padua, Italy
5Oncological Immunology and Molecular Diagnostic, Istituto Oncologico Veneto, Padua, Italy

Correspondence
Giuliana Rizzuto, Hematology and Bone Marrow Transplant Unit ASST Papa Giovanni XXIII Bergamo, Piazza OMS, 1, 24127 Bergamo, Italy.
Email: giuliana.rizzuto@unimi.it

Funding information
None

Abstract
The translocation t(8;9)(p22;p24) results in the production of a chimeric PCM1-JAK2 fusion protein leading to the constitutive activation of the Janus Kinase 2 that renders this disease potentially sensitive to ruxolitinib. Here, we report an interesting case of PCM1-JAK2 myeloproliferative neoplasm evolving in myeloid sarcoma and B precursor ALL.

Keywords
acute B-lymphoblastic leukemia, case report, myeloid sarcoma, PCM1-JAK2 myeloproliferative neoplasm, ruxolitinib

1 | BACKGROUND
The translocation t(8;9)(p22;p24) results in the production of a chimeric PCM1-JAK2 fusion protein leading to the constitutive activation of the Janus Kinase 2. It represents the driver mutation of a specific, extremely rare entity, recognized as provisional by the WHO (World Health Organization) classification: “Myeloid/Lymphoid neoplasm with eosinophilia and PCM1-JAK2 gene rearrangement”1,2

Giuliana Rizzuto and Matteo Leoncin contributed equally as co-first authors.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
The hematological trait shares common features with myeloproliferative neoplasm and myelodysplastic/myeloproliferative neoplasm. Hyperactivation of the JAK-STAT pathway renders this disease potentially sensitive to ruxolitinib; however, there are conflicting results about the duration of response and whether consolidation with allogeneic hematopoietic stem cell transplantation (alloHSCT) is indicated when a response is achieved.

Here, we report an interesting case of PCM1-JAK2 myeloproliferative neoplasm evolving in myeloid sarcoma and B precursor acute lymphoblastic leukemia (BCP-ALL), which required composite clinical management as well as an advanced molecular diagnostic approach in the follow-up.

2 | THE CASE

In November 2017, a 53-year-old woman was diagnosed with Myelofibrosis documented by histopathologic analysis showing a marrow hypercellularity, myeloid and erythroid hyperplasia, MF-2. BCR-ABL1 gene rearrangement and JAK2 mutations were negative. She was initially managed with a watch-and-wait approach. One year later, in March 2019, due to a rapidly worsening coxalgia, she underwent a PET/CT (Positron Emission Tomography/Computed Tomography) scan showing a neoformation infiltrating the right ilio-psoas muscle (Figure 1A). The ilio-psoas biopsy showed a myeloid infiltrate with medium-sized blasts with dispersed nuclear chromatin with one or two nucleoli; blasts were positive for MPO, CD33 e CD45 resulted in a diagnosis of myeloid sarcoma (Figure 2A,B). A bone marrow reassessment showed the presence of a blastic infiltration with dual phenotype: the major infiltrate consisting of 60% lymphoid blasts (CD10, CD19, CD34, CD45, CD52, TdT, CD38 positive but negative for intracytoplasmic immunoglobulins); the minor one consisting of myeloid blasts (Myeloperoxidase, CD33, CD45 positive) equal to 25–30%. Background hematopoietic cell composition was compatible with the underlying myeloproliferative disorder (Figure 3). Peripheral blood test showed normal values of hemoglobin (Hb 11.6 g/dl), leukocytes (6.64 × 10⁹/L), and platelets (424 × 10⁹/L), without evidence of blast. Cytogenetic analysis on the bone marrow specimen revealed the presence of the translocation t(8;9)(p22;p24) leading to the presence of PCM1-JAK2 fusion protein, as demonstrated by FISH analysis and by PCR (Polymerase chain reaction) and Nested PCR (Figure 4). Molecular biology for NPM1, FLT3-ITD, and point mutations, IDH1, IDH2, JAK2V617F, CALR tested using PCR resulted was negative. Targeted next-generation sequencing (NGS) performed using a capture-based method (Sophia Myeloid Solution, Sophia Genetics SA, Saint Sulpice, Switzerland selecting 30 gene regions associated with myelodysplastic syndrome, myeloproliferative neoplasms, and leukemia) was negative. Based on genetic results, we revised the initial diagnosis as PCM1-JAK2 neoplasm with a synchronous evolution into an isolated bone myeloid sarcoma and a BCP-ALL. In order to tackle myeloid and lymphoid diseases, the patient started induction with standard chemotherapy according to FLAI scheme (Fludarabine 30 mg/m² for 5 days, Cytarabine 2 g/m² for 5 days, and Idarubicine 10 mg/m² for 3 days), without combination with tyrosine kinase or JAK inhibitors. A bone marrow evaluation after induction revealed no evidence of residual AML. She was then consolidated with a second cycle of FLAI followed by a cycle with high-dose methotrexate and cytarabine, also for CNS prophylaxis. Finally, radiotherapy consolidation (30 Gy administered in 15 fractions) on the ilio-psoas myeloid sarcoma was performed. Restaging marrow showed a complete hematological response, but FISH studies revealed the persistence of the t(8;9) translocation in 23% of bone marrow (BM) cells. MRD analysis of immunoglobulin

FIGURE 1 (A, B) PET/CT scan showing ilio-psosas and iliac crest involvement before (Panel A) and after (Panel B) treatment
rearrangement showed a positive though not quantifiable signal; PET imaging showed complete remission of myeloid sarcoma (Figure 1B). Taken together, these results pointed toward an effective eradication of both myeloid sarcoma and BCP-ALL, yet with a persisting residual myeloproliferative background.

AlloHSCT was performed in September 2019, following myeloablative conditioning based on Busulphan 12.8 mg/kg and Fludarabine 160 mg/m², considering the aggressive disease course of this entity⁶ and the availability of a fully matched unrelated donor. Pre-transplant in vivo T-cell depletion with anti-thymocyte immunoglobulins (ATG, 5 mg/kg, Sanofi-Genzyme) followed by cyclosporine and short-course methotrexate post-transplant was used as GvHD (graft vs. host disease) prophylaxis.

To address the challenge of appropriate molecular monitoring after alloHSCT, we generated two different qPCR-based MRD assays exploiting not only the above described, patient-specific IgH recombination probe to monitor BP-ALL⁷ but also a PCM1-JAK2 fusion genespecific probe to detect residual myeloproliferative disease.

At day +60 after alloHSCT, a bone marrow evaluation revealed the persistence of the PCM1-JAK2 fusion transcript, while no residual BP-ALL MRD signal was detected. Therefore, we decided to start ruxolitinib treatment.
at the dosage of 10 mg/BID. By day +90 after alloHSCT, we documented a successful negativization of the $\text{PCM1-JAK2}$ MRD chimeric signal. Due to peripheral edema, ruxolitinib was decreased at day +120; this dose reduction was followed by a reappraisal of a weak MRD signal on bone marrow and peripheral blood. For this reason, a full ruxolitinib dosage was promptly reintroduced, and MRD negativity in peripheral blood was restored. The patient remains on ruxolitinib treatment, without significant side effects or infections at day +260 (Figure 5).

3 | DISCUSSION AND CONCLUSIONS

We report an unusual case of myeloproliferative neoplasm with the $\text{PCM1-JAK2}$ fusion t(8;9)(p22;p24), evolving in blast crisis of both lymphoid and myeloid lineages. To the best of our knowledge, this is the first case reporting the synchronous evolution in acute myeloid and acute lymphoblastic leukemia of a myeloproliferative neoplasm with $\text{PCM1-JAK2}$ fusion.8,9 The unique scenario of our case bestowed significant challenges in both diagnosis and treatment.

Identifying the $\text{PCM1-JAK2}$ fusion gene-specific probe is essential for a proper diagnostic workup that should guide personalized and risk-adapted therapy decisions, such as using ruxolitinib as targeted therapy and the early allocation of suitable patients to alloHSCT. In this patient, a more accurate molecular initial diagnosis could have prevented the rapid myeloid and lymphoid blastic transformation and perhaps the intensive cycles of chemotherapy, but most likely not the transplant choice. Moreover, this case report highlights the challenges in the clinical management of neoplasm involving different cell lineages. We speculated that a pediatric-like protocol for ALL or a conventional regimen was likely not sufficiently active to tackle this disease. Accordingly, fludarabine containing high-dose protocol was chosen and proved partially effective. The management of the underlying chronic neoplasm was another challenge since it could have led to an early recurrence of the disease. For this reason, as soon as complete remission was obtained, the patient underwent alloHSCT, and ruxolitinib therapy was started as post-transplant maintenance.

Ruxolitinib has been reported to be active against $\text{PCM1-JAK2}$ fusion genes neoplasms, and its use as bridging therapy before alloHSCT has been described.5,6,10 In our case, identifying a specific molecular marker offered the possibility to monitor the depth of remission after transplant and start an early preemptive therapy with ruxolitinib as soon as any evidence of disease reappraisal was documented. However, it is worthy to mention that the use of ruxolitinib in the post-transplant setting was not supported by evidence. In this patient, we decided to start ruxolitinib mainly taking into consideration the preliminary evidences in favor of a possible ability in suppressing the malignant clone5,6,10 and balancing the risk of recurrence that we considered significantly higher compared with potential risks of adverse effects. The reappraisal of a weak MRD signal after ruxolitinib dose reduction and

---

**FIGURE 5** Timeline of the PCM1-JAK2 fusion gene-specific probe evaluated on peripheral blood and on bone marrow. AlloHSCT, allogeneic hematopoietic stem cell transplantation, MS, myeloid sarcoma; BCP-ALL, B-cell precursor acute lymphoblastic leukemia
the negativity with full ruxolitinib dosage suggests that ruxolitinib was responsible for the successful therapeutic effect in the post-transplant in our patient, although the additive effect of the withdrawal of immunosuppression cannot formally be ruled out. In addition, it remains to be addressed whether this treatment should be continued indefinitely or if it could be discontinued.

ACKNOWLEDGEMENTS
None.

CONFLICTS OF INTERESTS
The authors declare no conflicts of interest.

AUTHOR CONTRIBUTION
GR, ML, and SI designed the study, followed the clinical course of the patient, collected data, drafted the manuscript, and gave the final approval before manuscript submission. DT, MCM, FL, and GB followed the clinical course of the patient and gave the final approval before manuscript submission. MT, OS, MP, and LB processed the samples, performed molecular and chimerism analyses, and gave the final approval before manuscript submission. FL contributed to the final writing of the paper and gave the final approval before manuscript submission. AR and CG supervised the study, revised the manuscript, and gave the final approval before manuscript submission.

ETHICAL APPROVAL
The study was approved by the local Institutional Review Board, and it was conducted in accordance with the Declaration of Helsinki.

CONSENT
Written informed consent was obtained from the patient to publish this report in accordance with the journal’s patient consent policy.

DATA AVAILABILITY STATEMENT
Data available on request from the authors.

ORCID
Giuliana Rizzuto https://orcid.org/0000-0001-7518-2521
Marco Pizzi https://orcid.org/0000-0003-4006-7317

REFERENCES